{"Clinical Trial ID": "NCT00802945", "Intervention": ["INTERVENTION 1:", "NKTR-102 14 days", "NKTR-102: NKTR-102 given on schedule q14 day", "INTERVENTION 2:", "NKTR-102 21 days", "NKTR-102: NKTR-102 given on schedule q21 days"], "Eligibility": ["Incorporation criteria:", "Inoperable or locally advanced metastatic breast cancer", "A taxane should not contain more than 2 previous chemotherapys administered in metastatic or locally advanced media and prior treatment in metastatic media.", "- Exclusion criteria:", "Patients undergoing chemotherapy or radiation therapy within 4 weeks (6 weeks for nitrosourea or mitomycin C) prior to day 1 of cycle 1", "Patients who have undergone major surgery within 4 weeks prior to day 1 of the cycle or minor surgery within 2 weeks prior to day 1 of cycle 1"], "Results": ["Performance measures:", "Objective response rate (ORR)", "By Response Assessment Criteria for Solid Tumours (RECIST v1.0) for Target and MRI-Assessed Injury: complete response (CR), elimination of all target lesions; partial response (PR), reduction of at least 30% in the sum of the longest diameter of target lesions; overall response (RO) = CR + PR.", "Time limit: Up to 2 years.", "Results 1:", "Title of arm/group: NKTR-102 14 days", "Description of the arm/group: NKTR-102: NKTR-102 given on a schedule q14 days", "Total number of participants analysed: 35", "Type of measurement: Number", "Unit of measure: percentage of subjects 28.6 (14.6 to 46.3)", "Results 2:", "Title of arm/group: NKTR-102 21 days", "Description of the arm/group: NKTR-102: NKTR-102 given on a 21-day schedule", "Total number of participants analysed: 35", "Type of measurement: Number", "Unit of measure: percentage of subjects 35 (14.6 to 46.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 18/35 (51.43 per cent)", "Anemia * 0/35 (0.00 %)", "Febrile Neutropenia * 0/35 (0.00 %)", "Neutropenia * 1/35 (2.86 %)", "\u2022 blurred vision * 1/35 (2.86 per cent)", "Abdominal pain * 1/35 (2.86%)", "Lower abdominal pain * 1/35 (2.86%)", "Constipation * 0/35 (0.00 %)", "Diarrhoea * 6/35 (17.14 per cent)", "Ileite * 0/35 (0.00 per cent)", "Nausea * 2/35 (5.71%)", "Small intestinal obstruction * 0/35 (0.00 %)", "Adverse Events 2:", "Total: 15/35 (42.86 per cent)", "Anemia * 1/35 (2.86%)", "Febrile Neutropenia * 1/35 (2.86 %)", "Neutropenia * 0/35 (0.00 %)", "Unsightly vision * 0/35 (0.00 %)", "Abdominal pain * 0/35 (0.00 %)", "Lower abdominal pain * 0/35 (0.00 %)", "Constipation * 1/35 (2.86 per cent)", "Diarrhoea * 4/35 (11.43%)", "ileitis * 1/35 (2.86 per cent)", "Nausea * 0/35 (0.00 %)", "Small intestinal obstruction * 1/35 (2.86%)"]}